The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Begbies Traynor Group PLC - Manchester, England-based.
Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland (BUSINESS WIRE) Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to.